West Pharmaceutical Services (WST) fundamentals: P/E, valuation, undervalued?
West Pharmaceutical Services · Health Care · ref. ETF XLV · price $371.82
In short — West Pharmaceutical Services trades at 47.6× earnings (P/E), 37.2× forward, with a net margin of 17.0 % and revenue growth of +14 %. Read: Somewhat expensive (P/E 37 high vs ~18% growth (PEG 2.1)).
Is West Pharmaceutical Services stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$371.82+42.4% over range
Oct 14, 25low $230.95 · high $376.76Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 9 analysts
Valuation : Somewhat expensive — P/E 37 high vs ~18% growth (PEG 2.1)
Valuation
47.6
P/E (price/earnings)
37.2
Forward P/E
2.63
PEG
8.8
Price/book (P/B)
$26.2B
Market cap
7.81
EPS
Profitability & growth
17.0 %
Net margin
+14 %
Revenue growth
+18 %
Earnings growth
$317M
Total debt
West Pharmaceutical Services income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $2.9B | $586M | 20.3 % |
| 2023 | $2.9B | $593M | 20.1 % |
| 2024 | $2.9B | $493M | 17.0 % |
| 2025 | $3.1B | $494M | 16.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is West Pharmaceutical Services's P/E and is the stock undervalued? What's a good P/E?
West Pharmaceutical Services's P/E is 47.6 (forward 37.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Somewhat expensive".
Is West Pharmaceutical Services profitable?
West Pharmaceutical Services has a net margin of 17.0 % (EPS 7.81). The company is profitable.
Is WST stock expensive?
Our read: "Somewhat expensive" — P/E 37 high vs ~18% growth (PEG 2.1). Cross-check with growth and sector.
💬 A question about West Pharmaceutical Services? The JPI assistant answers using our backtest data.
Keep exploring West Pharmaceutical Services